세계의 면역조직화학 시장 보고서 : 제품, 용도, 최종 용도 및 지역별(2024-2032년)

The global immunohistochemistry market size reached US$ 2.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.9 Billion by 2032, exhibiting a growth rate (CAGR) of 6.8% during 2024-2032. The rising prevalence of chronic diseases, the increasing demand for personalized medicines, significant advancements in diagnostic techniques, growing investments in healthcare infrastructure, and the rising aging population are some of the major factors propelling the growth of the market.

Immunohistochemistry Market Analysis:

• Major Market Drivers: The growing incidence of infectious and chronic diseases which necessitate advanced diagnostic solutions represent the major drivers of the market. The widespread adoption of personalized medicine, which relies heavily on biomarker identification is further stimulating the demand for immunohistochemistry. Significant technological advancements in diagnostic techniques enhance the accuracy and efficiency of immunohistochemistry tests.
• Key Market Trends: The increasing integration and automation of advanced imaging technologies to enhance diagnostic throughput and accuracy represents one of the key trends in the market. The rising shift toward companion diagnostic and precision medicine, emphasizes personalized treatment strategies. The growing development of multiplex assays allows simultaneous detection of multiple biomarkers thus increasing efficiency.
• Geographical Trends: North America accounts for the largest region in the immunohistochemistry market. The strong emphasis on cancer research and diagnostic advancements in Canada and the US is driving the market growth. This is primarily due to the substantial healthcare spending and well-established medical infrastructure. The widespread adoption of personalized medicine and biomarker-based testing, particularly in oncology is fueling the market growth across the region.
• Competitive Landscape: Some of the major market players in the immunohistochemistry industry include Abcam plc, Agilent Technologies Inc., Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, Bio SB Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Cell Signaling Technology Inc., F. Hoffmann-La Roche AG, Merck KGaA, Perkinelmer Inc. and Thermo Fisher Scientific Inc., among many others.
• Challenges and Opportunities: The market faces various challenges in the market including high costs associated with advanced imaging systems and reagents, a lack of skilled professionals capable of interpreting complex immunohistochemical data, and strict regulatory requirements for product approvals. However, the market faces several opportunities such as the rising demand for personalized medicine and targeted therapies that rely heavily on immunohistochemical markers for effective treatment planning.

Immunohistochemistry Market Trends:

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases including cancer is driving the demand for accurate diagnostic and prognostic tools. Immunohistochemistry is crucial for detecting biomarkers in cancer and other diseases, thus aiding in precise diagnosis and treatment planning. According to data published by the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The estimated number of people who were alive within 5 years following a cancer diagnosis was 53.5 million. About 1 in 5 people develop cancer in their lifetime, and approximately 1 in 9 men and 1 in 12 women die from the disease. This surge is aptly met by the key players by introducing more effective products and services. For instance, in April 2024, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit. The assay expands the company's Droplet Digital PCR (ddPCR) offering for the oncology market, where highly sensitive and multiplexed mutation detection assays aid translational research, therapy selection, and disease monitoring. This is further expected to boost the immunohistochemistry market forecast over the coming years.

Significant Technological Advancement

The growing technological innovations in microscopy, staining techniques, and digital imaging enhance the effectiveness and efficiency of immunohistochemistry procedures, thereby making it a preferred method for detailed tissue analysis. For instance, in May 2023, BD (Becton, Dickinson, and Company), a leading global medical technology company, announced the worldwide commercial launch of a new world sales sorting instrument offering two breakthrough technologies that enable researchers to uncover more detailed information about sales that were previously invisible in traditional flow cytometry experiments. With BD CellView Image Technology, researchers can see detailed microscopic images of individual cells and sort at high speeds based on visual characteristics to confirm insights in real time. With BD SpectalFX Technology, researchers can achieve full spectrum cell sorting, coupled with expanded performance enabled by a new modular optical architecture and system-aware algorithms, to perform high parameter experiments within a simplified workflow.

Rising Focus on Personalized Medicine

The increasing shift toward personalized medicine, especially in oncology, is driving the need for immunohistochemistry to identify specific molecular targets and tailor treatments to individual patient profiles, thus improving therapeutic outcomes. For instance, in June 2023, Thermo Fisher Scientific, the world leader in serving science, announced the launch of Gibco OncoPro Tumor Roid Culture Medium Kit, the first commercially available culture medium specifically developed for the expansion of patient-derived tumoroids, or cancer organoids, from multiple cancer indications. Similarly, in January 2023, Apollo Cancer Center, Bengaluru, launched India's first AI Precision Oncology Center (POC) in a significant move that will substantially enhance the quality of oncology care. The Center will help the oncologists, patients, and caregivers to arrive at the best possible results in a time-bound manner the enormous possibilities offered by AI. This is influencing the immunohistochemistry market revenue across the globe.

Immunohistochemistry Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on product, application, and end-use.

Breakup by Product:

• Antibodies
  • Primary Antibodies
  • Secondary Antibodies
• Equipment
  • Slide Staining Systems
  • Tissue Microarrays
  • Tissue Processing Systems
  • Slide Scanners
  • Others
• Reagents
  • Histological Stains
  • Blocking sera and Reagents
  • Chromogenic Substrates
  • Fixation Reagents
  • Stabilizers
  • Organic Solvents
  • Proteolytic Enzymes
  • Diluents
• Kits

Antibodies accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the product. This includes antibodies (primary and secondary), equipment (slide staining systems, tissue microarrays, tissue processing systems, slide scanners, and others), reagents (histological stains, blocking Sera and Reagents, chromogenic substrates, fixation reagents, stabilizers, organic solvents, proteolytic enzymes, and diluents), and kits. According to the report, Antibodies represented the largest segment.

The increasing need for disease diagnosis and research, especially cancers and infectious diseases is elevating the demand for specific antibodies. The rising innovations in antibody engineering improve specificity and sensitivity, enhancing diagnostic accuracy. The expanding biomedical research necessitates diverse antibodies for detailed cellular and molecular studies. Personalized treatment approaches require precise biomarker identification, boosting the use of targeted antibodies. For instance, in August 2023, Regeneron Pharmaceuticals, Inc. announced that the Biomedical Advanced Research and Development (BARDA)authority has agreed with Regeneron to support clinical development, clinical manufacturing, and the regulatory licensure process of on next-generation COVID-19 monoclonal antibody therapy for the prevention of SARS-CoV-2 infection.

Breakup by Application:

• Diagnostics
  • Cancer
  • Infectious Diseases
  • Cardiovascular Diseases
  • Autoimmune Diseases
  • Diabetes Mellitus
  • Nephrological Diseases
• Drug Testing

Diagnostics holds the largest share of the industry

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes diagnostics (cancer, infectious diseases, cardiovascular diseases, autoimmune diseases, diabetes mellitus, and nephrological diseases) and drug testing. According to the report, diagnostics accounted for the largest market share.

The increasing cases of cardiovascular, infectious diseases, cancer, autoimmune, nephrological conditions, and diabetes necessitate advanced diagnostic methods. In line with this, the enhancing focus on personalized treatment plans based on specific biomarkers detected through immunohistochemistry. Significant improvements in staining techniques and emerging technologies improve the accuracy and efficiency of disease diagnosis. The growing research activities require detailed cellular analysis, promoting the use of immunohistochemistry in understanding disease mechanisms and pathology. This is further driving the demand for diagnostics in the immunohistochemistry market growth.

Breakup by End-Use:

• Hospitals and Diagnostic Laboratories
• Research Institutes
• Others

Hospitals and Diagnostic Laboratories represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the end-use. This includes hospitals and diagnostic laboratories, research institutes, and others. According to the report, hospitals and diagnostic laboratories represented the largest segment.

The rising rates of chronic diseases particularly cancers, are driving the demand for precise diagnostic tools such as immunohistochemistry to accurately identify and classify disease states. Significant innovations in digital imaging systems and staining techniques enhance the diagnostic capabilities and throughput of immunohistochemistry, making it more appealing for clinical settings. The rising focus on adherence to high quality and regulatory standards in diagnostic processes necessitates reliable techniques like immunohistochemistry. The increasing investments in healthcare infrastructure and diagnostic services boost the adoption of advanced diagnostic methods, such as immunohistochemistry, in both developed and emerging markets.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest immunohistochemistry market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for immunohistochemistry.

The rising cases of cancer and other chronic conditions are driving the demand for precise diagnostic methods like immunohistochemistry to identify biomarkers for effective treatment which is influencing the market growth across the region. The well-established healthcare facilities and robust funding research and development (R&D) are facilitating the adoption of advanced diagnostic technologies. According to the data from the National Library of Medicine, in 2024, 2,001,140 new cancer cases and 611,720 cancer deaths are projected to occur in the United States. Cancer mortality continued to decline through 2021, averting over 4 million deaths since 1991 because of reductions in smoking, earlier detection for some cancers, and improved treatment options in both adjuvant and metastatic settings.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the immunohistochemistry industry include Abcam plc, Agilent Technologies Inc., Beckman Coulter Inc. (Danaher Corporation), Becton Dickinson and Company, Bio SB Inc., Bio-Rad Laboratories Inc., Bio-Techne Corporation, Cell Signaling Technology Inc., F. Hoffmann-La Roche AG, Merck KGaA, Perkinelmer Inc. and Thermo Fisher Scientific Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

• The market is highly competitive, with key players like Agilent Technologies, Thermo Fisher Scientific, and Roche Diagnostics dominating. These players focus on innovation and strategic partnerships to enhance their product portfolios. Other significant companies such as Merk Group, Bio-Rad Laboratories, and Danaher Corporation, emphasize expanding their global footprints through collaborations and acquisitions. In February 2023, Agilent Technologies Inc. introduced an integrated solution that combines their xCELLigence RTCA HT platform with the Bio Tek BioSpa 8 Automated Incubator. This new development offers a higher level of workflow automation, allowing further creation of label-free high throughput potency assays for immune-oncology and high throughput viral cytopathic effects (CPE) assays for the vaccine market.

Immunohistochemistry Market News:

• In August 2023, global science and technology provider Danaher signed the definitive agreement for the acquisition of all outstanding stakes in UK-based protein consumables supplier Abcam in a deal valued at $5.7 bn.
• In January 2024, Agilent Technologies Inc. announced an agreement with Incyte that will bring together Agilent's expertise and proven track record in the development of companion diagnostics (CDx) to support the development of commercialization of Incyte's hematology and oncology portfolio.
• In June 2022, Merck, a leading science and technology company, announced that it has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0.

Key Questions Answered in This Report:

• How has the global immunohistochemistry market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global immunohistochemistry market?
• What is the impact of each driver, restraint, and opportunity on the global immunohistochemistry market?
• What are the key regional markets?
• Which countries represent the most attractive immunohistochemistry market?
• What is the breakup of the market based on the product?
• Which is the most attractive product in the immunohistochemistry market?
• What is the breakup of the market based on the application?
• Which is the most attractive application in the immunohistochemistry market?
• What is the breakup of the market based on the end-use?
• Which is the most attractive end-use in the immunohistochemistry market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global immunohistochemistry market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Immunohistochemistry Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Antibodies
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Primary Antibodies
    • 6.1.2.2 Secondary Antibodies
  • 6.1.3 Market Forecast
• 6.2 Equipment
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Slide Staining Systems
    • 6.2.2.2 Tissue Microarrays
    • 6.2.2.3 Tissue Processing Systems
    • 6.2.2.4 Slide Scanners
    • 6.2.2.5 Others
  • 6.2.3 Market Forecast
• 6.3 Reagents
  • 6.3.1 Market Trends
  • 6.3.2 Key Segments
    • 6.3.2.1 Histological Stains
    • 6.3.2.2 Blocking sera and Reagents
    • 6.3.2.3 Chromogenic Substrates
    • 6.3.2.4 Fixation Reagents
    • 6.3.2.5 Stabilizers
    • 6.3.2.6 Organic Solvents
    • 6.3.2.7 Proteolytic Enzymes
    • 6.3.2.8 Diluents
  • 6.3.3 Market Forecast
• 6.4 Kits
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Application

• 7.1 Diagnostics
  • 7.1.1 Market Trends
  • 7.1.2 Key Segments
    • 7.1.2.1 Cancer
    • 7.1.2.2 Infectious Diseases
    • 7.1.2.3 Cardiovascular Diseases
    • 7.1.2.4 Autoimmune Diseases
    • 7.1.2.5 Diabetes Mellitus
    • 7.1.2.6 Nephrological Diseases
  • 7.1.3 Market Forecast
• 7.2 Drug Testing
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by End Use

• 8.1 Hospitals and Diagnostic Laboratories
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Research Institutes
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abcam plc
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Agilent Technologies Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Beckman Coulter Inc. (Danaher Corporation)
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Becton Dickinson and Company
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Bio SB Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Bio-Rad Laboratories Inc.
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Bio-Techne Corporation
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
  • 14.3.8 Cell Signaling Technology Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 F. Hoffmann-La Roche AG
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 SWOT Analysis
  • 14.3.10 Merck KGaA
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
    • 14.3.10.4 SWOT Analysis
  • 14.3.11 Perkinelmer Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Thermo Fisher Scientific Inc.
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis